Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

BALLI-01 abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL populationNEW YORK, May 11, 2023 -- Cellectis , a clinical-stage biotechnology company... | May 11, 2023

Related Keywords

Raleigh ,North Carolina ,United States ,New York ,Paris ,France General ,France ,Germany ,Mark Frattini ,Ashleyr Robinson ,Nicolas Boissel ,Pascalyne Wilson ,Arthur Stril ,Youtube ,Nasdaq ,Cellectis The Company Euronext Growth ,Securities Exchange Commission ,Linkedin ,European Hematology Association ,Euronext Growth ,Hybrid Congress ,Chief Medical Officer ,Updated Results ,B Cell Acute Lymphoblastic Leukemia ,Lassistance Publique ,Nasdaq Global Market ,Private Securities Litigation Reform Act ,Annual Report ,Chief Business Officer ,Lifesci Advisors ,Cellectis Sa Stock Exchange ,News ,Information ,Press Release ,Abstract ,Emonstrates ,Safety ,End ,Reliminary ,Efficacy ,F ,Cart22 ,N ,Heavily ,Pretreated ,Opulationnew ,Bay ,023 ,Cellectis ,Iotechnology Alcls Fr0010425595 ,